세포 신호전달 시장 - 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 기술별, 경로별, 지역별, 부문별 예측(2024-2030년)

Cell Signaling Market Growth & Trends:

The global cell signaling market size is expected to reach USD 8.94 billion by 2030, according to a new report by Grand View Research, Inc. The market is estimated to register a CAGR of 7.56% from 2024 to 2030. A rising emphasis on stem cell research significantly contributes to the growth and development of the cell signaling industry. Stem cells provide a model system to study the intricate processes of cellular differentiation and development. Cell signaling pathways play a crucial role in directing stem cells toward specific cell differentiation, rendering cell signaling technology a dependable tool that significantly contributes to overall market expansion.

Furthermore, stem cells also play a pivotal role in drug discovery and disease modeling, with cell signaling research providing essential knowledge on the pathways modulated by therapeutic compounds and the dysregulations observed in various diseases. Rising government funding further boosts developments in stem cell research. For instance, in March 2020, Canada's government allocated approximately USD 7 million towards regenerative medicine and stem cell research with an aim to support nine transnational projects and four clinical trials within the country, contributing to the expansion of the regenerative medicine sector. Therefore, as the demand for stem cells rises, it consequently propels market growth for cell signaling process.

Additionally, technological advancements such as rising omics technologies play a significant role in driving market growth. Omics technologies facilitate the identification of biomarkers associated with specific cell signaling events.These biomarkers serve as indicators of normal cellular function or aberrations linked to diseases, which plays a crucial role in early disease detection, prognosis, and monitoring treatment responses. Thus, the application of these technologies enhances the understanding of cell signaling pathways and contributes significantly to the growth of the cell signaling industry.

Cell Signaling Market Report Highlights:

• Based on type, endocrine signaling dominated the market with a revenue share of 42.9% in 2023. The increased prevalence of endocrine-related disorders such as adrenal insufficiency, Cushing's disease, gigantism, hypothyroidism, as well as hyperthyroidism is one of the primary drivers driving market expansion
• In terms of product, consumables held the largest revenue share of 58.3% in 2023. This has been ascribed to the increasing need for cell signaling as a result of byproducts that include reagents, test kits, and antibodies. Expansion of the medical supplies industry is another factor driving segment demand
• On the basis of technology, microscopy dominates the market with a revenue share of 35.8% in 2023. The factors that can be linked to technological breakthroughs in recent years have accelerated the development of light microscopy, which is boosting demand for this segment
• Based on pathway, the AKT signaling pathway segment held a dominant share of 43.1% in 2023. The predicted development of commercial diagnostic tests based on AKT pathway downregulation will drive the cell signaling sector to flourish over the forecast timeframe
• North America dominated the global industry in 2023 with a revenue share of 40.3%, owing to the presence of key market players in this region. Majority of the key companies in this region's cell signaling industry have been actively involved in R&D activities involving cell signaling pathways

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
• 1.2. Information analysis
• 1.3. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Cell Signaling Market: Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Cell Signaling Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising incidence of chronic diseases
  • 3.4.2. Technological advancement in cell based signaling research
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost associated with cell signaling research
• 3.6. Business Environment Analysis
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTLE Analysis
  • 3.6.3. COVID-19 Analysis

Chapter 4. Cell Signaling Market: Type Estimates & Trend Analysis

• 4.1. Cell Signaling Market: Type Movement Analysis
• 4.2. Endocrine Signaling
  • 4.2.1. Endocrine Signaling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.3. Paracrine Signaling
  • 4.3.1. Paracrine Signaling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Autocrine Signaling
  • 4.4.1. Autocrine Signaling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Others
  • 4.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cell Signaling Market: Product Estimates & Trend Analysis

• 5.1. Cell Signaling Market: Product Movement Analysis
• 5.2. Consumables
  • 5.2.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.3. Instruments
  • 5.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cell Signaling Market: Technology Estimates & Trend Analysis

• 6.1. Cell Signaling Market: Technology Movement Analysis
• 6.2. Flow Cytometry
  • 6.2.1. Flow Cytometry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.3. Microscopy
  • 6.3.1. Microscopy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Western Blotting
  • 6.4.1. Western Blotting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. ELISA
  • 6.5.1. ELISA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cell Signaling Market: Pathway Estimates & Trend Analysis

• 7.1. Cell Signaling Market: Pathway Movement Analysis
• 7.2. AKT Signaling Pathway
  • 7.2.1. AKT Signaling Pathway Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. AMPK Signaling Pathway
  • 7.3.1. AMPK Signaling Pathway Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. ErbB/HER Signaling Pathway
  • 7.4.1. ErbB/HER Signaling Pathway Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Other Signaling Pathways
  • 7.5.1. Other Signaling Pathways Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Cell Signaling Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Cell Signaling Market 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. U.S. Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.2.3. CANADA
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Canada Cell Signaling Market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. UK Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.3.3. GERMANY
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. Germany Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.3.4. SPAIN
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. Spain Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.3.5. FRANCE
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. France Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.3.6. ITALY
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. Italy Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.3.7. DENMARK
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Denmark Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.3.8. SWEDEN
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Target Disease Prevalence
    • 8.3.8.5. Sweden Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.3.9. NORWAY
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Target Disease Prevalence
    • 8.3.9.5. Norway Cell Signaling Market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia-Pacific Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.4.2. JAPAN
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Japan Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.4.3. CHINA
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. China Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.4.4. INDIA
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. India Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.4.5. SOUTH KOREA
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Target Disease Prevalence
    • 8.4.5.5. South Korea Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.4.6. THAILAND
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Target Disease Prevalence
    • 8.4.6.5. Thailand Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.4.7. AUSTRALIA
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Target Disease Prevalence
    • 8.4.7.5. Australia Cell Signaling Market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.5.2. BRAZIL
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. Brazil Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.5.3. MEXICO
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Mexico Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.5.4. ARGENTINA
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. Argentina Cell Signaling Market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.6.2. SOUTH AFRICA
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. South Africa Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.6.3. SAUDI ARABIA
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. Saudi Arabia Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Target Disease Prevalence
    • 8.6.4.5. UAE Cell Signaling Market, 2018 - 2030 (USD Million)
  • 8.6.5. KUWAIT
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Target Disease Prevalence
    • 8.6.5.5. Kuwait Cell Signaling Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. Acquisitions
  • 9.2.2. Product/Service Launches
  • 9.2.3. Partnerships/Collaborations
  • 9.2.4. Others
• 9.3. Market Position Analysis, 2023
• 9.4. Company Profiles
  • 9.4.1. Thermo Fisher Scientific, Inc.
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. QIAGEN
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Becton, Dickinson and Company
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Bio-Rad Laboratories Inc.
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Bio-Techne Corporation
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Cell Signaling Technology Inc.
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Benchmarking
    • 9.4.6.3. Strategic Initiatives
  • 9.4.7. Danaher
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Merck KGaA
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. PerkinElmer Inc.
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Promega Corporation
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives